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Abstract
Rapid advances in sequencing technologies set the stage for the large-scale medical sequencing efforts to be performed in
the near future, with the goal of assessing the importance of rare variants in complex diseases. The discovery of new disease
susceptibility genes requires powerful statistical methods for rare variant analysis. The low frequency and the expected large
number of such variants pose great difficulties for the analysis of these data. We propose here a robust and powerful testing
strategy to study the role rare variants may play in affecting susceptibility to complex traits. The strategy is based on
assessing whether rare variants in a genetic region collectively occur at significantly higher frequencies in cases compared
with controls (or vice versa). A main feature of the proposed methodology is that, although it is an overall test assessing a
possibly large number of rare variants simultaneously, the disease variants can be both protective and risk variants, with
moderate decreases in statistical power when both types of variants are present. Using simulations, we show that this
approach can be powerful under complex and general disease models, as well as in larger genetic regions where the
proportion of disease susceptibility variants may be small. Comparisons with previously published tests on simulated data
show that the proposed approach can have better power than the existing methods. An application to a recently published
study on Type-1 Diabetes finds rare variants in gene IFIH1 to be protective against Type-1 Diabetes.
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Introduction
Common diseases such as diabetes, heart disease, schizophre-
nia, etc., are likely caused by a complex interplay among many
genes and environmental factors. At any single disease locus allelic
heterogeneity is expected, i.e., there may be multiple, different
susceptibility mutations at the locus conferring risk in different
individuals [1].
Common and rare variants could both be important contrib-
utors to disease risk. Thus far, in a first attempt to find disease
susceptibility loci, most research has focused on the discovery of
common susceptibility variants. This effort has been helped by the
widespread availability of genome-wide arrays providing almost
complete genomic coverage for common variants. The genome-
wide association studies performed so far have led to the discovery
of many common variants reproducibly associated with various
complex traits, showing that common variants can indeed affect
risk to common diseases [2,3]. However, the estimated effect sizes
for these variants are small (most odds ratios are below 1:5), with
only a small fraction of trait heritability explained by these variants
[4]. For example, at least 40 loci have been identified for height,
but these loci together explain only 5% of the 80% estimated
heritability for this trait [5]. One possible explanation for this
missing heritability is that, in addition to common variants, rare
variants are also important.
Evidence to support a potential role for rare variants in complex
traits comes from both empirical and theoretical studies. There is
an increasing number of recent studies on obesity, autism,
schizophrenia, epilepsy, hypertension, HDL cholesterol, some
cancers, Type-1 diabetes etc. [6–15] that implicate rare variants
(both single position variants and structural variants) in these traits.
From a theoretical point of view, population genetics theory
predicts that most disease loci do not have susceptibility alleles at
intermediate frequencies [16,17].
With rapid advances in next-generation sequencing technolo-
gies it is becoming increasingly feasible to efficiently sequence large
number of individuals genome-wide, allowing for the first time a
systematic assessment of the role rare variants may play in
influencing risk to complex diseases [18–21]. The analysis of the
resulting rare genetic variation poses many statistical challenges.
Due to the low frequencies of rare disease variants (as low as 0:001,
and maybe lower) and the large number of rare variants in the
genome, studies with realistic sample sizes will have low power to
detect such loci one at a time, the way we have done in order to
find common susceptibility variants [5,22]. It is then necessary to
perform an overall test for all rare variants in a gene or, more
generally a candidate region, under the expectation that cases with
disease are different with respect to rare variants compared with
control individuals. Several methods along these lines have already
been proposed. One of the first statistical methods proposed for
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proportion of carriers of rare variants is significantly different
between cases and controls. A subsequent paper by Madsen and
Browning [24] introduced the concept of weighting variants
according to their estimated frequencies in controls, so that less
frequent variants are given higher weight compared with more
common variants. Price et al. [25] extended the weighted-sum
approach in [24] to weight variants according to externally-
defined weights, such as the probability of a variant to be
functional. One potential drawback for these methods is that they
are very sensitive to the presence of protective and risk variants.
We introduce here a new testing strategy, which we call
replication-based strategy, and which is based on a weighted-sum
statistic, but that has the advantage of being less sensitive to the
presence of both risk and protective variants in a genetic region of
interest. We illustrate the proposed approach on simulated data,
and a real sequence dataset on Type-1 diabetes.
Methods
We assume for ease of exposition, and without loss of generality,
that an equal number of cases and controls have been sequenced
in a genetic region of interest. In what follows, for the sake of
fixation, we will be concerned with the situation where rare
variants in the region increase susceptibility to disease. We discuss
first a one-sided testing strategy to test for the presence of variants
conferring risk to disease.
We partition the variants observed in cases and controls into
distinct groups, according to the observed frequencies of the minor
allele in cases and controls. More precisely, group (k,k’) contains
all variants that have exactly k copies of the minor allele in
controls, and exactly k’ copies of the minor allele in cases. Let nk’
k
be the size of group (k,k’). Note that the set of nk’
k represents a
summary of the original data, that in some sense contains all the
information the data can tell us about the presence of disease
variants in the region under investigation. For the purpose of
testing for the presence of risk variants, we choose to focus only on
variants that are likely to be risk variants, i.e., those variants with
k’wk. A summary of the data is shown in Table 1.
We define the following weighted-sum statistic, where each
variant in group (k,k’) is assigned a weight wk’
k , and hence:
S~
X Nr
k~0
X
k’wk
nk’
k wk’
k ð1Þ
where Nr is an upper threshold on the number of occurrences of a
variant in controls.
The choice of a good weighting scheme is very important for the
performance of the approach. There are several possible ways to
define the weights, including several already in the literature.
Madsen and Browning [24] use data-dependent weights, with
wk’
k ~
k’
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pU(1{pU)
p ,
where pU~
kz1
2(nUz1)
is the estimated frequency based on controls
only, and nU is the number of controls. Price et al. [25] discuss the
possibility of incorporating external weights, based on predictions
about variants being functional.
For our approach we define a set of data-dependent weights, as
follows. For a variant that occurs k times in controls and k’ times
in cases with k’wk, a natural weight is the negative log of the
probability of a variant occurring at most k times in controls and
at least k’ times in cases, under the null hypothesis of the variant
not being associated with the disease:
wk’
k ~{log½p(k,k’)  fork’wk:
The statistic S above can then be written as:
S~
X Nr
k~0
X
k’wk
{nk’
k log½p(k,k’) :
Since the number of mutations at a rare variant position follows
approximately a Poisson distribution, the probability p(k,k’) of
observing at a variant position at most k mutations in controls, and
at least k’ mutations in cases is calculated as
p(k,k’)~ppois(k, ^ f f):(1{ppois(k’{1, ^ f f)),
where ^ f f~(kzk’)=2 is the estimated variant frequency based on
the observed number of occurrences in both cases and controls,
and ppois is the Poisson distribution function. Note that the higher
the observed frequency in cases compared with controls (i.e., the
higher k’{k), the higher the weight will be, and hence S tends
to be larger when more variants are seen at higher frequencies
in cases versus controls. We employ a standard permutation
Table 1. Data summary.
k/k9 12345...
0 n1
0 n2
0 n3
0 n4
0 n5
0 ...
1 n2
1 n3
1 n4
1 n5
1 ...
2 n3
2 n4
2 n5
2 ...
3 n4
3 n5
3 ...
4 n5
4 ...
...
Variants are classified according to the number of times they appear in controls
(k) and cases (k’). Only variants with higher observed count in cases compared
with controls (i.e., more likely to be risk variants) are considered.
doi:10.1371/journal.pgen.1001289.t001
Author Summary
Risk to common diseases, such as diabetes, heart disease,
etc., is influenced by a complex interaction among genetic
and environmental factors. Most of the disease-association
studies conducted so far have focused on common
variants, widely available on genotyping platforms. How-
ever, recent advances in sequencing technologies pave the
way for large-scale medical sequencing studies with the
goal of elucidating the role rare variants may play in
affecting susceptibility to complex traits. The large number
of rare variants and their low frequencies pose great
challenges for the analysis of these data. We present here a
novel testing strategy, based on a weighted-sum statistic,
that is less sensitive than existing methods to the presence
of both risk and protective variants in the genetic region
under investigation. We show applications to simulated
data and to a real dataset on Type-1 Diabetes.
Testing for Association with Rare Variants
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permuting the case/control label, and repeating the procedure
described above for each permuted dataset, thus quantifying the
extent to which the observed value of S is significantly higher
compared to the null expectation.
The strategy described above is inherently one-sided, because
we focus on variants that have higher observed frequency in cases
compared with controls, i.e., more likely to be risk variants. This
test can be used symmetrically to test for the presence of protective
variants. Without any prior knowledge on the direction of the
association, two one-sided statistics need to be computed. If Sz
and S{ are the two one-sided statistics as defined in eq. (1), then a
max-statistic can be used that calculates the maximum of the two,
i.e., max(Sz,S{), and the statistical significance can be assessed
by permutation.
Incorporation of External Biological Information
If external information is available on the plausibility of a rare
variant to be related to disease, it is of interest to be able to
incorporate such information into our testing strategy. Such
information has proved essential in the mapping of the disease
genes for two monogenic disorders [26], and may well prove
important for mapping disease genes in more complex diseases. It
is straightforward to extend the proposed approach to take into
account such information. If we denote by Q(v) the probability
that a variant v is functional, then we can rewrite the statistic S
above as:
S~
X Nr
k~0
X
k’wk
X
v[(k,k’)
{Q(v)log½p(k,k’) ,
where v[(k,k’) signifies that variant v occurs k times in controls,
and k’ times in cases. In particular, if Q(v)~1 for all variants v
then we recover the statistic S above, where functional information
was not used. If on the other hand a variant is not functional, then
Q(v)~0, and this variant is ignored.
Results
Simulated Data
Simulation model. We evaluated both the Type-1 error and
the power for the proposed approach using data simulated under
various genetic and disease models, and compared the results to
those obtained using several existing approaches. Li and Leal [23]
proposed one of the very first statistical methods for association
testing with rare variants, based on collapsing rare variants in a
genetic region together. In this approach, each individual is called
a carrier if the individual contains at least one rare variant in the
region. Then the strategy is to assess whether the proportion of
carriers in affected individuals is significantly different from the
proportion of carriers in unaffected individuals. A subsequent
approach proposed by Madsen and Browning [24] is based on a
weighted-sum statistic. A feature of this approach, especially
relevant in large samples, is that variants are weighted according
to their estimated frequencies from unaffected individuals, such
that less frequent variants are assigned higher weights compared to
more frequent variants.
The first set of simulations is based on a neutral Wright-Fisher
model. Using the software package Genome [27] we generated
10,000 haplotypes according to a coalescent model, resulting in a
total of 183 single nucleotide variants (SNVs) in the region (see
Text S1 for more details). For the second set of simulations,
we assume that the rare variants in the region are under weak
purifying selection (as discussed in [16]), and use Wright’s
distribution [28] to sample the frequency at each variant:
f(p)~cpbs{1(1{p)
bn{1es(1{p),
where bs and bn are scaled mutation rates, and s is the selection
rate; c is a normalizing constant. As in [16] and [24], we take
bs~0:001, bn~bs=3, and s~12. The main difference between
the two simulation models is that the variant frequency spectra are
different, with proportionally more rare variants under the second
model compared with the first model (e.g., 141 out of the total of
183 variants have frequency below 0:01 under the second model,
while only 83 have this low frequency under the first model).
With respect to the disease model, we assume varying number
of disease susceptibility variants (DSVs) between 10 and 30, chosen
at random from the generated polymorphisms that had low
frequency (less than 0:01). We assume two possible values for the
total population attributable risk (PAR): 0:03 and 0:05. The total
PAR is distributed among all the disease variants. In one scenario,
all disease variants have the same PAR, equal to the total PAR
divided by the number of disease susceptibility variants. Perhaps a
more realistic scenario is to assume unequal PAR for the different
DSVs, and to this end we assume that individual variants’ PARs
are uniformly sampled from ½0,1 , and then renormalized to make
them sum to the same total PAR of 0:03 or 0:05. In addition to
the uniform distribution, we have also used an exponential model
for the distribution of the individual PARs. In Supplemental
Figure S-1 in Text S5 we show an example of the possible
relationship between the odds ratio and the frequency at a disease
variant, assuming 20 disease variants with frequencies between
0:0001 and 0:01, and a total PAR of 0:03 or 0:05.
Type-1 error. We evaluated the Type-1 error for both the
proposed and the existing approaches using the two simulation
models discussed above (neutral and weakly-purifying selection).
We assume two possible sample sizes, 1000 and 2000, with equal
number of cases and controls. As shown in Table 2, the Type-1
Table 2. Type-1 Error for the three approaches: collapsing (C),
weighted-sum (WSt), and replication-based (R).
Sim.
Model
Sample
Size a CW S t R
1 1000 0:050 0:044 0:053 0:051
0:025 0:022 0:027 0:025
0:010 0:007 0:010 0:011
1 2000 0:050 0:055 0:043 0:052
0:025 0:027 0:022 0:025
0:010 0:012 0:010 0:008
2 1000 0:050 0:044 0:049 0:048
0:025 0:023 0:027 0:022
0:010 0:010 0:011 0:012
2 2000 0:050 0:047 0:051 0:050
0:025 0:019 0:029 0:027
0:010 0:008 0:011 0:012
Results for two genetic simulation models are shown: variants under a neutral
evolution model (1), and variants under a weakly-purifying selection model (2).
The sample size is the total number of individuals sequenced, with equal
numbers of cases and controls. Nominal a levels: 0:05, 0:025,a n d0:01.
doi:10.1371/journal.pgen.1001289.t002
Testing for Association with Rare Variants
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0:01 for all three methods.
Power. We evaluated the power for all three methods
assuming two models for generating the genetic data, and several
complex disease models. For the genetic data, as explained above,
two scenarios are illustrated: a first one where the variant fre-
quencies are generated using a neutral coalescent model, and a
second one where the variants are under weakly-purifying selection.
For the underlying disease models, a varied number of disease
susceptibility variants are assumed, that contribute equally, or
unequally to the total PAR. For the latter scenario, the individual
variant PAR are sampled from a uniform distribution (results for an
exponential sampling distribution areshown in Supplemental Table
S-1 in Text S3). To make the comparison fair among the different
methods considered the same threshold of 0:01 was used on the
frequency of the variants included in the three testing methods.
Power estimates for a series of simulation experiments are
shown in Table 3. Note that the results are based on two-sided
testing for all three methods and a~0:05. For the same total PAR,
the power decreases with increasing number of disease variants,
due to the correspondingly smaller contribution of each disease
variant. Also, the power increases for all methods when the
weakly-purifying selection simulation model is used as opposed to
the neutral model, due to the lower number of rare variants that
are actually observed under the former model compared with
the latter model. However, given the same sampling distribution
for the frequency of the variants, the power did not vary much
between the different ways the individual PARs were sampled.
The key factor is the total PAR for the region. Overall the
proposed approach is consistently and substantially more powerful
than both the collapsing and the weighted-sum approaches across
the multiple scenarios that we have considered, and under both
models to generate the variant frequencies.
Sensitivity to presence of both risk and protective
variants. So far we have assumed scenarios where only variants
that increase risk are present in a genetic region. However,
sometimes it may be the case that both risk and protective variants
are present in a genetic region of interest, for example when multiple
genes in a set or pathway are tested together. This can also be true
when individuals from the two extremes of a phenotype distribution
are chosen to be studied. In such situations, the two existing methods
discussed can suffer substantial loss of power, depending on the
relative contributions of the two classes of variants. We show here
that the proposed approach is less sensitive to such mixture, the
principal reason being the inclusion of only those variants that may
confer risk, and exclusion of the variants that are unlikely to be risk
variants when we test for the presence of risk variants, and similarly
when we test for the presence of protective variants.
Table 3. Power Estimates (a~0:05) for the three approaches: collapsing (C) versus weighted-sum (WSt) versus replication-based (R).
PAR=0.03 PAR=0.05
Sim. Model Sample Size Disease Model #DSVs C WSt RCW S t R
1 1000 Eq PAR 10 0:223 0:248 0:344 0:522 0:673 0:753
20 0:210 0:242 0:331 0:474 0:514 0:690
30 0:174 0:201 0:301 0:438 0:480 0:668
1 2000 Eq PAR 10 0:427 0:610 0:743 0:828 0:966 0:985
20 0:384 0:521 0:701 0:783 0:917 0:975
30 0:334 0:447 0:661 0:706 0:876 0:966
1 1000 Uneq PAR 10 0:214 0:276 0:367 0:514 0:670 0:768
20 0:203 0:224 0:324 0:487 0:548 0:707
30 0:163 0:210 0:298 0:442 0:469 0:652
1 2000 Uneq PAR 10 0:414 0:646 0:753 0:834 0:957 0:982
20 0:394 0:551 0:712 0:769 0:920 0:972
30 0:344 0:485 0:658 0:744 0:880 0:959
2 1000 Eq PAR 10 0:278 0:417 0:537 0:569 0:828 0:901
20 0:262 0:310 0:481 0:538 0:724 0:870
30 0:230 0:259 0:431 0:513 0:650 0:845
2 2000 Eq PAR 10 0:478 0:843 0:921 0:868 0:999 1:000
20 0:455 0:762 0:911 0:859 0:996 1:000
30 0:387 0:671 0:885 0:817 0:984 0:999
2 1000 Uneq PAR 10 0:265 0:385 0:494 0:586 0:854 0:893
20 0:240 0:349 0:478 0:569 0:757 0:890
30 0:235 0:276 0:455 0:494 0:680 0:846
2 2000 Uneq PAR 10 0:480 0:859 0:924 0:882 0:996 1:000
20 0:431 0:761 0:899 0:860 0:993 0:999
30 0:414 0:708 0:880 0:814 0:988 0:999
Two genetic simulation models are assumed: neutral variants (1), and mildly deleterious variants (2). Varying number of DSVs are assumed, that can contribute equally
or unequally to the total PAR. The sample size is the total number of individuals sequenced, with equal numbers of cases and controls. All tests are two-sided, i.e.,
testing for the presence of risk or protective variants in the region of interest.
doi:10.1371/journal.pgen.1001289.t003
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presence of risk or protective variants, given the existence of both
risk and protective variants in the region. We assume that there
are 20 risk variants in the region, and the number of protective
variants is between 0 and 20. As in the previous simulations, the
total PAR for the 20 risk variants can take two values, 0:03 and
0:05, while each protective variant has the same per-variant PAR,
equal to the total PAR divided by 20. Therefore, when the number
of protective variants is 20 the overall contribution to disease is the
same for risk and protective variants. This is of course the worst
case scenario, and the Collapsing and Weighted-Sum approaches
suffer from substantial loss of power in such cases. Even the
proposed approach is not insensitive to such scenarios; however
the loss in power is considerably less than that for the other two
methods.
Type-1 Diabetes Dataset
We also applied our approach to a dataset on Type 1 Diabetes
(T1D), published by Nejentsev et al. [15]. In their paper, the
authors resequenced exons and splice sites of ten candidate genes
in 480 cases and 480 controls (more details on the dataset are in
Text S2). In their study, rare variants were tested individually, and
two SNVs in gene IFIH1 and two other SNVs in gene CLEC16A
were found to be protective against T1D.
Here we reanalyze the dataset using the proposed approach,
and two of the existing approaches. For each gene and each
method, we perform two-sided tests, testing for the presence of risk
or protective variants. Results are in Table 5. As in [15] we found
one gene, IFIH1, to be significant with all three methods (P-
valuev0:001 for all three methods). For this gene, controls were
enriched for rare mutations compared with cases. Some evidence
of enrichment in protective variants was also observed in another
gene, CLEC16A, although the P-values do not remain significant
after multiple testing correction.
Discussion
We have proposed here a new testing strategy to examine
associations between rare variants and complex traits. The
approach is based on a weighted-sum statistic that makes efficient
use of the information the data provides on the presence of disease
variants in the region being investigated. The proposed test is
based on computing two one-sided statistics, designed to quantify
enrichment in risk variants, and protective variants, respectively.
This aspect allows the proposed approach to have substantially
better power than existing approaches in the presence of both risk
and protective variants in a region. Even when only one kind of
variants is present, we have shown via simulations that the
proposed approach has consistently better power than existing
approaches. An application to a previously published dataset on
Type-1 Diabetes [15] confirmed the original finding, namely that
rare variants in IFIH1 confer protection towards disease.
Theweightsunderlyingourweighted-sumstatisticdependonlyon
the data at hand. However, external information on the likelihood of
a variant to be functional could prove very useful, and could be
combinedwiththe information presentinthe data toimprove power
to identify disease susceptibility variants. Such information has been
successfully used to identify the genes for several monogenic dis-
orders [26]. Price et al. [25] discuss a weighted-sum approach with
externally-derived weights, and show that such information can be
veryusefulusing several empirical datasets.Wehave alsodescribed a
natural way to take into account such external functional predictions
within the proposed framework.
Since empirical data are only now becoming available, it is not
known how often both risk and protective variants are present in a
particular disease gene. When both types of variants are present, it
seems appealing to be able to combine the two types of signals. It is
possible to extend the proposed approach to take advantage of
both kinds of disease variants, and we discuss such an extension in
Text S4. We noticed in our simulation experiments that such a
hybrid approach can have much improved power when both types
of variants are present, but this comes at the price of reduced
power when only one type of variants is present. Therefore,
depending on the underlying disease model, both approaches
could provide useful information.
Table 4. Power Estimates (a~0:05) for two-sided tests, testing for the presence of risk or protective variants, when there is a
mixture of risk and protective variants in the region of interest.
PAR=0.03 PAR=0.05
Sim. Model #Risk #Protective C WSt RCW S t R
12 0 0 0 :210 0:242 0:331 0:474 0:514 0:690
50 :132 0:164 0:263 0:281 0:389 0:567
10 0:081 0:126 0:202 0:145 0:300 0:476
20 0:056 0:102 0:183 0:044 0:209 0:478
22 0 0 0 :262 0:310 0:481 0:538 0:724 0:870
50 :155 0:212 0:383 0:336 0:559 0:788
10 0:095 0:185 0:314 0:160 0:438 0:697
20 0:054 0:133 0:286 0:056 0:320 0:711
In addition to 20 risk variants in the region, there are between 0{20 protective variants as well. Simulation model corresponds to one of the two scenarios: neutral
variants (1), and mildly deleterious variants (2). The total sample size is 1000 cases and controls. Collapsing (C) vs. weighted-Sum (WSt) vs. replication-based (R).
doi:10.1371/journal.pgen.1001289.t004
Table 5. Type-1 diabetes results.
Gene #SNVs C WSt R
IFIH1 29 0:0005 0:0002 0:0001
CLEC16A 45 0:030 0:022 0:014
Two-sided P-values for the top two genes. An upper frequency threshold of
0:01 was used for the variants considered for testing.
doi:10.1371/journal.pgen.1001289.t005
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and therefore is susceptible to spurious findings due to population
stratification. Population stratification has been shown to be an
important issue in the context of common variants. For rare
variants, differences in rare variant frequencies between popula-
tions are likely to be even more pronounced. Development of new
methods, and extension of existing methods are necessary to
adequately address the issue. Alternatively, family-based designs
offer the advantage of being robust to false positive findings due to
population stratification.
Replication of association signals in independent datasets is an
essential aspect of any disease association study, and has become
standard practice for common variants. Rare variants, due to their
low frequencies and potential modest effects, are normally tested
together with other rare variants in the same unit, e.g., gene.
Therefore a reasonable first replication strategy is at the level of
the gene. Follow-up of individual variants in the gene can be
performed to investigate whether any of the rare variants in the
gene can be found to be significantly associated with disease.
Finding rare disease susceptibility variants is a challenging
problem, especially due to their low frequencies and the probable
moderate effects on disease. So far the methods proposed in the
literature have focused on case-control designs. However, for rare
variants, family-based designs may prove very useful. Not only are
they robust against population stratification, but they may also
offer increased power due to the increased likelihood of affected
relatives to share the same rare disease variants. Continued
development of novel statistical methods for identifying rare
disease susceptibility variants is needed for population-based
designs, and especially for family-based designs.
Software implementing these methods is available at: http://
www.mailman.columbia.edu/our-faculty/profile?uni=ii2135.
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